International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.78 Million USD | -4.78% |
| 2022 | 8.18 Million USD | 13.99% |
| 2021 | 7.17 Million USD | 0.67% |
| 2020 | 7.12 Million USD | -24.75% |
| 2019 | 9.47 Million USD | -14.58% |
| 2018 | 11.08 Million USD | 48.73% |
| 2017 | 7.45 Million USD | 4.06% |
| 2016 | 7.16 Million USD | -5.11% |
| 2015 | 7.55 Million USD | 7.61% |
| 2014 | 7.01 Million USD | 14.15% |
| 2013 | 6.14 Million USD | 34.6% |
| 2012 | 4.56 Million USD | 0.77% |
| 2011 | 4.53 Million USD | 188.94% |
| 2010 | 1.56 Million USD | 39.9% |
| 2009 | 1.12 Million USD | 123.0% |
| 2008 | 502.77 Thousand USD | 1197.0% |
| 2007 | 38.76 Thousand USD | 1270.72% |
| 2006 | 2828.00 USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.12 Million USD | 12.71% |
| 2024 Q2 | 2.33 Million USD | 9.49% |
| 2023 Q4 | 1.88 Million USD | -4.26% |
| 2023 Q1 | 2.08 Million USD | -14.16% |
| 2023 Q2 | 1.84 Million USD | -11.74% |
| 2023 FY | 7.78 Million USD | -4.78% |
| 2023 Q3 | 1.97 Million USD | 7.17% |
| 2022 Q2 | 2.02 Million USD | 0.35% |
| 2022 FY | 8.18 Million USD | 13.99% |
| 2022 Q4 | 2.43 Million USD | 42.69% |
| 2022 Q3 | 1.7 Million USD | -15.98% |
| 2022 Q1 | 2.02 Million USD | 9.6% |
| 2021 Q2 | 1.83 Million USD | 10.55% |
| 2021 Q3 | 1.84 Million USD | 0.49% |
| 2021 FY | 7.17 Million USD | 0.67% |
| 2021 Q1 | 1.65 Million USD | 12.33% |
| 2021 Q4 | 1.84 Million USD | 0.05% |
| 2020 Q2 | 1.81 Million USD | -23.22% |
| 2020 FY | 7.12 Million USD | -24.75% |
| 2020 Q3 | 1.48 Million USD | -18.27% |
| 2020 Q4 | 1.47 Million USD | -0.34% |
| 2020 Q1 | 2.36 Million USD | -16.81% |
| 2019 Q1 | 2.21 Million USD | -0.22% |
| 2019 Q4 | 2.83 Million USD | 35.35% |
| 2019 FY | 9.47 Million USD | -14.58% |
| 2019 Q2 | 2.32 Million USD | 4.64% |
| 2019 Q3 | 2.09 Million USD | -9.69% |
| 2018 Q2 | 3.03 Million USD | 15.38% |
| 2018 Q4 | 2.22 Million USD | -30.42% |
| 2018 FY | 11.08 Million USD | 48.73% |
| 2018 Q1 | 2.63 Million USD | 42.94% |
| 2018 Q3 | 3.19 Million USD | 5.17% |
| 2017 Q3 | 1.84 Million USD | 4.82% |
| 2017 FY | 7.45 Million USD | 4.06% |
| 2017 Q1 | 2 Million USD | 18.64% |
| 2017 Q4 | 1.84 Million USD | -0.27% |
| 2017 Q2 | 1.76 Million USD | -12.12% |
| 2016 FY | 7.16 Million USD | -5.11% |
| 2016 Q4 | 1.69 Million USD | -13.02% |
| 2016 Q3 | 1.94 Million USD | 1.41% |
| 2016 Q2 | 1.91 Million USD | 18.56% |
| 2016 Q1 | 1.61 Million USD | -18.3% |
| 2015 Q3 | 2.13 Million USD | 17.69% |
| 2015 Q2 | 1.81 Million USD | 11.9% |
| 2015 FY | 7.55 Million USD | 7.61% |
| 2015 Q1 | 1.62 Million USD | -10.73% |
| 2015 Q4 | 1.97 Million USD | -7.4% |
| 2014 FY | 7.01 Million USD | 14.15% |
| 2014 Q4 | 1.81 Million USD | -7.44% |
| 2014 Q1 | 1.64 Million USD | -4.96% |
| 2014 Q2 | 1.58 Million USD | -3.7% |
| 2014 Q3 | 1.96 Million USD | 23.61% |
| 2013 Q4 | 1.73 Million USD | 3.89% |
| 2013 FY | 6.14 Million USD | 34.6% |
| 2013 Q1 | 1.28 Million USD | 3.05% |
| 2013 Q2 | 1.45 Million USD | 13.39% |
| 2013 Q3 | 1.67 Million USD | 14.62% |
| 2012 Q4 | 1.24 Million USD | 5.05% |
| 2012 FY | 4.56 Million USD | 0.77% |
| 2012 Q1 | 1.07 Million USD | 1.54% |
| 2012 Q2 | 1.05 Million USD | -1.95% |
| 2012 Q3 | 1.18 Million USD | 12.41% |
| 2011 Q3 | 842.05 Thousand USD | -24.43% |
| 2011 Q2 | 1.11 Million USD | -26.44% |
| 2011 FY | 4.53 Million USD | 188.94% |
| 2011 Q1 | 1.51 Million USD | 199.54% |
| 2011 Q4 | 1.06 Million USD | 25.97% |
| 2010 Q2 | 441.11 Thousand USD | 61.8% |
| 2010 Q1 | 272.62 Thousand USD | 8.88% |
| 2010 FY | 1.56 Million USD | 39.9% |
| 2010 Q3 | 348.98 Thousand USD | -20.89% |
| 2010 Q4 | 505.75 Thousand USD | 44.92% |
| 2009 Q1 | 183.29 Thousand USD | 40.26% |
| 2009 Q4 | 250.39 Thousand USD | -16.16% |
| 2009 Q3 | 298.66 Thousand USD | -23.19% |
| 2009 Q2 | 388.81 Thousand USD | 112.12% |
| 2009 FY | 1.12 Million USD | 123.0% |
| 2008 Q4 | 130.68 Thousand USD | -39.9% |
| 2008 Q2 | 122.3 Thousand USD | 278.27% |
| 2008 Q1 | 32.33 Thousand USD | 52.88% |
| 2008 FY | 502.77 Thousand USD | 1197.0% |
| 2008 Q3 | 217.45 Thousand USD | 77.8% |
| 2007 FY | 38.76 Thousand USD | 1270.72% |
| 2007 Q4 | 21.14 Thousand USD | 70.07% |
| 2007 Q1 | 1826.00 USD | 108.89% |
| 2007 Q2 | 3355.00 USD | 83.73% |
| 2007 Q3 | 12.43 Thousand USD | 270.64% |
| 2006 Q2 | - USD | -100.0% |
| 2006 FY | 2828.00 USD | 0.0% |
| 2006 Q1 | 1752.00 USD | 0.0% |
| 2006 Q4 | -20.54 Thousand USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -10186.039% |
| Evofem Biosciences, Inc. | 18.21 Million USD | 57.246% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 93.665% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -303.157% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | 50.618% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -44102.94% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | 63.735% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -11750.353% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -31.972% |
| Marizyme, Inc. | 645.81 Thousand USD | -1106.082% |
| Genus plc | 668.8 Million USD | 98.835% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 96.825% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -7768.154% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1798.992% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -10047.08% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -19610.006% |
| MultiCell Technologies, Inc. | 49.32 USD | -15792681.833% |
| ONE Bio Corp. | 52.29 Million USD | 85.106% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 84.335% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -15828.425% |
| Q BioMed Inc. | 284.35 Thousand USD | -2639.211% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | 73.683% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 94.632% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -1296.604% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -11027.143% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -1082.84% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.947% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -779579.68% |
| Enzolytics Inc. | 52.79 Thousand USD | -14653.012% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -1179.98% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 99.365% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -5453.971% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -1161.614% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 99.072% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -680.675% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | 83.892% |
| BioStem Technologies, Inc. | 16.68 Million USD | 53.318% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -3192.611% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -3192.611% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -468.955% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -1544.186% |
| SYBLEU INC | 11.69 Thousand USD | -66495.417% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -59815.385% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -19602.029% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -133.904% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -16.864% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -649.663% |
| Gelesis Holdings, Inc. | 25.76 Million USD | 69.771% |
| CSL Limited | 14.8 Billion USD | 99.947% |
| Cellectis S.A. | 755 Thousand USD | -931.656% |